Cargando…

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients

With the introduction of novel therapeutic agents, survival in Multiple Myeloma (MM) has increased in recent years. However, drug-resistant clones inevitably arise and lead to disease progression and death. The current International Myeloma Working Group response criteria are broad and make it diffi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tierney, Ciara, Bazou, Despina, Majumder, Muntasir M., Anttila, Pekka, Silvennoinen, Raija, Heckman, Caroline A., Dowling, Paul, O’Gorman, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213739/ https://www.ncbi.nlm.nih.gov/pubmed/34145309 http://dx.doi.org/10.1038/s41598-021-90149-y

Ejemplares similares

S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma
por: Liu, Minxia, et al.
Publicado: (2021)

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
por: Miettinen, Juho J., et al.
Publicado: (2021)

Prognostic significance of esterase gene expression in multiple myeloma
por: Kumari, Romika, et al.
Publicado: (2021)

Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach
por: Katsenou, Angeliki, et al.
Publicado: (2023)

Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches
por: Dowling, Paul, et al.
Publicado: (2021)

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing
por: Majumder, Muntasir Mamun, et al.
Publicado: (2017)

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures
por: Dunphy, Katie, et al.
Publicado: (2023)

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
por: Blum, Agnieszka, et al.
Publicado: (2018)

Clinical Proteomics of Biofluids in Haematological Malignancies
por: Dunphy, Katie, et al.
Publicado: (2021)

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types
por: Majumder, Muntasir M., et al.
Publicado: (2020)

Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers
por: Dunphy, Katie, et al.
Publicado: (2021)

Marizomib: A novel therapeutic approach for the treatment of central nervous system myeloma
por: Bazou, Despina, et al.
Publicado: (2020)

A germline exome analysis reveals harmful POT1 variants in multiple myeloma patients and families
por: Hakkarainen, Marja, et al.
Publicado: (2022)

Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients
por: Ting, Kay Reen, et al.
Publicado: (2017)

Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy
por: Luoma, Sini, et al.
Publicado: (2023)

Bleeding and Thrombosis in Multiple Myeloma: Platelets as Key Players during Cell Interactions and Potential Use as Drug Delivery Systems
por: Kulkarni, Anushka, et al.
Publicado: (2023)

Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer
por: Malyutina, Alina, et al.
Publicado: (2019)

Bone Disease in Multiple Myeloma: Pathophysiology and Management
por: Hameed, Abdul, et al.
Publicado: (2014)

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
por: Jantunen, Esa, et al.
Publicado: (2023)

ALI multilayered co-cultures mimic biochemical mechanisms of the cancer cell-fibroblast cross-talk involved in NSCLC MultiDrug Resistance
por: Movia, Dania, et al.
Publicado: (2019)

The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death
por: Flanagan, Ken, et al.
Publicado: (2022)

Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013
por: Remes, Kari, et al.
Publicado: (2018)

Multilayered Cultures of NSCLC cells grown at the Air-Liquid Interface allow the efficacy testing of inhaled anti-cancer drugs
por: Movia, Dania, et al.
Publicado: (2018)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
por: Hartley-Brown, Monique, et al.
Publicado: (2022)

Civil society involvement in harm reduction drug policy: reflections on the past, expectations for the future
por: O’Gorman, Aileen, et al.
Publicado: (2021)

Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis
por: Ho Zhi Guang, Matthew, et al.
Publicado: (2019)

Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease
por: Dowling, Paul, et al.
Publicado: (2014)

Long-term outcome after allogeneic stem cell transplantation in multiple myeloma
por: Luoma, Sini, et al.
Publicado: (2021)

RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
por: Luoma, Sini, et al.
Publicado: (2019)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
por: Kuusanmäki, Heikki, et al.
Publicado: (2017)

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
por: Alzrigat, Mohammad, et al.
Publicado: (2017)

Multiple Myeloma: A Review of Imaging Features and Radiological Techniques
por: Healy, C. F., et al.
Publicado: (2011)

Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005–2016
por: Toppila, Iiro, et al.
Publicado: (2022)

Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report
por: Waterhouse, Deirdre F, et al.
Publicado: (2009)

Molecular diagnostics of a single drug-resistant multiple myeloma case using targeted next-generation sequencing
por: Ikeda, Hiroshi, et al.
Publicado: (2015)

No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects
por: Vourvahis, M, et al.
Publicado: (2010)

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma
por: Silvennoinen, R, et al.
Publicado: (2014)

Expected Next-Generation Drugs
por: Kim, Khae Hawn
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_iv5klh7m19404bldmj15917pe3